What's Going On With Regeneron Pharmaceuticals Stock On Friday? [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or doesn't respond to treatment (refractory). Similarly, R/R diffuse large B-cell lymphoma (DLBCL) occurs when DLBCL relapses or doesn't respond to therapy. The European Commission is expected to announce a final decision in the coming months. Also Read: Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs FL and DLBCL are the two most common subtypes of B-cell non-Hodgkin lymphoma (B-NHL). It is estimated that approximately 120,000 FL cases and 163,000 DLBCL cases are diagnosed annually worldwide. In Europe, it is estimated that approximately 15,000 FL cases and 31,000 DLBCL cases are di
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGNGlobeNewswire
- The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Make ContactAccesswire
- Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma [Yahoo! Finance]Yahoo! Finance
- Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaGlobeNewswire
- Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024GlobeNewswire
REGN
Earnings
- 5/2/24 - Beat
REGN
Sec Filings
- 7/1/24 - Form 144
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- REGN's page on the SEC website